

# Nour K Majbour

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6005953/publications.pdf>

Version: 2024-02-01

34  
papers

1,943  
citations

331259

21  
h-index

377514

34  
g-index

35  
all docs

35  
docs citations

35  
times ranked

2475  
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel engineered nanobodies specific for N-terminal region of alpha-synuclein recognize Lewy-body pathology and inhibit <i>in vitro</i> seeded aggregation and toxicity. FEBS Journal, 2022, 289, 4657-4673.	2.2	9
2	Î±-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2109617119.	3.3	60
3	Preanalytical Stability of CSF Total and Oligomeric Alpha-Synuclein. Frontiers in Aging Neuroscience, 2021, 13, 638718.	1.7	8
4	Cerebrospinal Î±-Synuclein Oligomers Reflect Disease Motor Severity in <scp>DeNoPa</scp> Longitudinal Cohort. Movement Disorders, 2021, 36, 2048-2056.	2.2	21
5	Cerebrospinal Fluid Î±-Synuclein Species in Cognitive and Movements Disorders. Brain Sciences, 2021, 11, 119.	1.1	14
6	Small molecule inhibitors of Î±-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans. Molecular Neurodegeneration, 2021, 16, 77.	4.4	13
7	CSF or Serum Neurofilament Light Added to Î±-Synuclein Panel Discriminates Parkinson's From Controls. Movement Disorders, 2020, 35, 288-295.	2.2	69
8	CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson's Disease. International Journal of Molecular Sciences, 2020, 21, 8519.	1.8	7
9	Fibrillar form of Î±-synuclein-specific scFv antibody inhibits Î±-synuclein seeds induced aggregation and toxicity. Scientific Reports, 2020, 10, 8137.	1.6	9
10	CSF total and oligomeric Î±-Synuclein along with TNF-Î± as risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers. Translational Neurodegeneration, 2020, 9, 15.	3.6	32
11	Safety and immunogenicity of the Î±-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial. Lancet Neurology, The, 2020, 19, 591-600.	4.9	83
12	Generation of monoclonal antibodies against phosphorylated Î±-Synuclein at serine 129: Research tools for synucleinopathies. Neuroscience Letters, 2020, 725, 134899.	1.0	12
13	Investigating the presence of doubly phosphorylated Î±-synuclein at tyrosine 125 and serine 129 in idiopathic Lewy body diseases. Brain Pathology, 2020, 30, 831-843.	2.1	15
14	Plasma-derived therapy: can the survivors of COVID-19 help the defenseless?. Diagnosis, 2020, 7, 373-376.	1.2	2
15	Parkinson's disease biomarkers based on Î±-synuclein. Journal of Neurochemistry, 2019, 150, 626-636.	2.1	104
16	Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration. Journal of Neuroinflammation, 2018, 15, 129.	3.1	131
17	Î±-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies. Movement Disorders, 2018, 33, 1724-1733.	2.2	79
18	Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer's disease. Scientific Reports, 2017, 7, 40263.	1.6	51

#	ARTICLE	IF	CITATIONS
19	Holocranohistochemistry enables the visualization of $\hat{\pm}$ -synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects. <i>Journal of Neural Transmission</i> , 2017, 124, 721-738.	1.4	42
20	Differential effects of immunotherapy with antibodies targeting $\hat{\pm}$ -synuclein oligomers and fibrils in a transgenic model of synucleinopathy. <i>Neurobiology of Disease</i> , 2017, 104, 85-96.	2.1	72
21	Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice. <i>Scientific Reports</i> , 2017, 7, 16533.	1.6	110
22	Cognitive impairment in Parkinson's disease. <i>Lancet Neurology</i> , The, 2017, 16, 23-24.	4.9	7
23	P2â€63: Performance Evaluation of New Absorbanceâ€Based Elisas for Measuring Different Alphaâ€Synuclein (Aâ€SYN) Species in CSF and Plasma. <i>Alzheimer's and Dementia</i> , 2016, 12, P677.	0.4	1
24	P4â€316: Standardization of Preâ€Analytical Procedures for Collection and Storage of CSF for the Measurement of Neurogranin Trunc P75 and â€Synuclein. <i>Alzheimer's and Dementia</i> , 2016, 12, P1155.	0.4	0
25	A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein. <i>Molecular Neurodegeneration</i> , 2016, 11, 61.	4.4	39
26	Longitudinal changes in CSF alphaâ€synuclein species reflect Parkinson's disease progression. <i>Movement Disorders</i> , 2016, 31, 1535-1542.	2.2	120
27	Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinsonâ€s disease. <i>Molecular Neurodegeneration</i> , 2016, 11, 7.	4.4	198
28	Brain propagation of transduced $\hat{\pm}$ -synuclein involves non-fibrillar protein species and is enhanced in $\hat{\pm}$ -synuclein null mice. <i>Brain</i> , 2016, 139, 856-870.	3.7	78
29	Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders. <i>Molecular Therapy</i> , 2016, 24, 746-758.	3.7	38
30	Generation and characterization of novel conformation-specific monoclonal antibodies for $\hat{\pm}$ -synuclein pathology. <i>Neurobiology of Disease</i> , 2015, 79, 81-99.	2.1	116
31	Ser129 phosphorylation of endogenous $\hat{\pm}$ -synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function. <i>Neurobiology of Disease</i> , 2015, 78, 100-114.	2.1	24
32	Differential role of CSF alpha-synuclein species, tau, and Aâ€242 in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 53.	1.7	139
33	Elevated levels of cerebrospinal fluid Aâ€synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 248.	1.7	59
34	Levels of cerebrospinal fluid $\hat{\pm}$ -synuclein oligomers are increased in Parkinsonâ€s disease with dementia and dementia with Lewy bodies compared to Alzheimerâ€s disease. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 25.	3.0	169